All In Biotech

Drug Trial Radar · NCT07800871

FT839 in Autoimmune Diseases

An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

446

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2028

Study completion Oct 2040

Sponsor

Lead sponsor
Fate TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.

Conditions

  • ANCA-Associated Vasculitis (AAV)
  • Idiopathic Inflammatory Myositis (IIM)
  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)

Interventions

  • FT839Biological

    Single Intravenous (IV) infusion of FT839 administered on Day 1 and Day 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of Dose-limiting Toxicity, Adverse Events, and Serious Adverse EventsTime frame: From enrollment to the end of the post-treatment follow-up at 2 years
  2. Phase 2: Change from baseline in Birmingham Vasculitis Activity ScoreTime frame: From enrollment to the end of the post-treatment follow-up at 2 years
  3. Phase 2: Change from baseline in Manual muscle testing-8Time frame: From enrollment to the end of the post-treatment follow-up at 2 years
  4. Phase 2: Change from baseline in Disease Activity Score using 28 joint counts and C-reactive protein (a composite measure)Time frame: From enrollment to the end of the post-treatment follow-up at 2 years
  5. Phase 2: Change from baseline in SLE Disease Activity Index 2000Time frame: From enrollment to the end of the post-treatment follow-up at 2 years
  6. Phase 2: Change from baseline in Modified Rodnan skin scoreTime frame: From enrollment to the end of the post-treatment follow-up at 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Providence Medical Foundation

    Fullerton, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.